Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Regadenoson
Drug ID BADD_D01921
Description Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Indications and Usage Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
Marketing Status approved; investigational
ATC Code C01EB21
DrugBank ID DB06213
KEGG ID D05711
MeSH ID C430916
PubChem ID 219024
TTD Drug ID D0XE1C
NDC Product Code 55150-443; 0409-1401; 76329-3321; 42973-229; 76055-0024; 60505-6116; 72611-874; 59285-029; 69766-103; 68083-175; 16729-477; 71288-201; 0641-6253; 65129-1331; 43598-616; 0469-6501; 62147-0220; 36000-364
UNII 2XLN4Y044H
Synonyms regadenoson | Lexiscan | CVT 3146 | CVT3146 | CVT-3146
Chemical Information
Molecular Formula C15H18N8O5
CAS Registry Number 313348-27-5
SMILES CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infusion site erythema08.02.05.008; 12.07.05.009; 23.03.06.0160.000288%-
Dysstasia08.01.03.089; 15.03.05.011; 17.02.02.0120.000228%-
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Cardiac flutter02.03.02.012---
Musculoskeletal discomfort15.03.04.001---
Injection site swelling08.02.03.017; 12.07.03.0180.001582%-
Infusion site pain08.02.05.014; 12.07.05.0020.001911%-
Infusion site swelling08.02.05.002; 12.07.05.0030.000863%-
Electrocardiogram PR prolongation13.14.05.012---
Injection site discomfort08.02.03.018; 12.07.03.0190.001006%-
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000474%-
Vasodilation procedure25.03.01.001---
Angiopathy24.03.02.007---
Abdominal symptom07.01.06.0070.000085%-
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Limb discomfort15.03.04.0140.000414%-
Ischaemia24.04.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Ill-defined disorder08.01.03.049---
Inner ear disorder04.04.02.002---
Renal impairment20.01.03.010---
Infusion site extravasation08.02.05.007; 12.07.05.0080.006225%
Supraventricular tachyarrhythmia02.03.03.014---
Bronchial hyperreactivity22.03.01.016---
Complication associated with device08.07.01.0110.000575%-
Anal incontinence07.01.06.029; 17.05.01.0210.000846%
Psychogenic seizure17.12.03.042; 19.24.01.0070.000085%-
Seizure like phenomena17.12.03.0300.000296%-
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages